The Value Case for European Pharma Stocks in 2026

In this episode, Lucas and Luna explore why European pharmaceutical companies are emerging as a compelling value play in mid-2026. With the S&P 500 hitting new highs and US pharma giants trading at elevated multiples, European pharma stocks like Novartis, Sanofi, and Bayer offer single-digit price-to-earnings ratios and dividend yields above 4 percent. The hosts discuss how the patent cliff overhang is already priced in, why the US biotech boom is creating a spillover effect for European contract manufacturers, and how the strong dollar is adding a tailwind for US-based investors. Lucas points out that the iShares MSCI Europe Financials ETF may not be the only value opportunity across the Atlantic. Tune in for a focused look at a corner of the market that most value investors are overlooking. #EuropeanPharma #ValueInvesting #Novartis #Sanofi #Bayer #PharmaStocks #DividendYield #PatentCliff #BiotechSpillover #StrongDollar #InternationalValue #LowPEMultiple #FexingoBusiness #BusinessPodcast #Finance #Investing #StockPicking #LongTermInvesting Keep every episode free: buymeacoffee.com/fexingo